Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients.
229E
COVID-19
D-dimer
HKU1
NL63
OC43
SARS-CoV-2
antibodies
complement
endothelium
neutralisation assay
von Willebrand factor
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
received:
02
05
2022
revised:
06
06
2022
accepted:
08
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
The severity of coronavirus disease 2019 (COVID-19) may be influenced by pre-existing immune responses against endemic coronaviruses, but conflicting data have been reported. We studied 148 patients who were hospitalised because of a confirmed diagnosis of COVID-19, classified mild in 58, moderate in 44, and severe in 46. The controls were 27 healthy subjects. At admission, blood samples were collected for the measurement of biomarkers of disease severity and levels of the IgG against the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and pre-existing coronaviruses OC43, HKU1, NL63 and 229E. Higher levels of IgG antibodies against the RBD of pre-existing coronavirus (with the highest significance for anti-HKU1 IgG,
Identifiants
pubmed: 35744709
pii: microorganisms10061191
doi: 10.3390/microorganisms10061191
pmc: PMC9228214
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
J Clin Virol. 2021 Jun;139:104847
pubmed: 33965698
Cell Rep. 2021 Dec 28;37(13):110169
pubmed: 34932974
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Emerg Microbes Infect. 2021 Dec;10(1):664-676
pubmed: 33734013
Cell Host Microbe. 2022 Jan 12;30(1):83-96.e4
pubmed: 34965382
J Med Virol. 2021 Dec;93(12):6444-6446
pubmed: 34260066
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
J Autoimmun. 2021 Feb;117:102595
pubmed: 33453462
Nat Commun. 2021 Feb 19;12(1):1152
pubmed: 33608538
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Autoimmun. 2021 Jan;116:102560
pubmed: 33139116
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Clin Lab. 2018 Apr 1;64(4):433-442
pubmed: 29739066
J Allergy Clin Immunol. 2020 Jul;146(1):215-217
pubmed: 32417135
Cell Rep. 2022 May 31;39(9):110904
pubmed: 35617962
Nat Commun. 2021 Jan 4;12(1):6
pubmed: 33397903
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32997649
Science. 2021 Oct 08;374(6564):eabh1823
pubmed: 34465633
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Nature. 2021 May;593(7859):424-428
pubmed: 33767445
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Commun. 2021 Nov 18;12(1):6703
pubmed: 34795285
Blood Rev. 2021 Mar;46:100745
pubmed: 32868115
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
Blood. 2020 Oct 29;136(18):2080-2089
pubmed: 32877502
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Biomedicines. 2021 Aug 12;9(8):
pubmed: 34440207
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096